|
|
Post by akemp3000 on Jan 26, 2019 5:48:18 GMT -5
Would love to see a press release reporting that the Purdue study shows the "dry powder inhaler formulation allows more than 60 percent of drugs to be delivered to the lungs than the 10% offered by a jet nebulizer...along with improved chemical stability". Further that "such approach can be readily applied to many antibiotic compounds, including those for tuberculosis".
This gives reason to believe the pharma world and the public will eventually learn that TS is the next generation drug delivery system. As long and as slow as this process has been, it's hard to imagine the next generation will use any needles for prandial insulin or any other drug delivery where inhalation is possible. Maybe there should be a marketing campaign on this topic alone that wouldn't have the FDA oversight restrictions since no drug would have to be mentioned. All it takes is one giant BP to awaken and fund this opportunity.
|
|
|
|
Post by travis1953 on Jan 27, 2019 9:47:58 GMT -5
New 2-in-1 powder aerosol to upgrade fight against deadly superbugs in lungs—December 12, 2018 Now, Purdue researchers have invented a drug formulation that uses two synergistic antibiotics – colistin and ciprofloxacin – in one single particle that is shown to reach the infection sites in the deep lung area with the capability to kill multi-drug-resistant superbugs.“We are providing a promising option to fight the global crisis of antimicrobial resistance,” said Qi (Tony) Zhou, an assistant professor in Purdue’s College of Pharmacy, who leads the research team. “It has been a worldwide challenge to incorporate two antibiotics with different chemical properties into a single particle. Our novel formulation allows for a much more effective killing of drug-resistant bacteria in the deep lungs as two synergistic antibiotics can be simultaneously delivered to the same infection site.” Zhou said the technology is designed to save tens of thousands of lives from a variety of deadly lung infections, including people with cystic fibrosis and ventilator-assisted pneumonia. The Purdue innovation is a dry powder inhaler formulation, which is proving to be more effective and easier to use than conventional inhalation products delivered through nebulizers in most hospitals. Zhou said the Purdue formulation allows for more than 60 percent of drugs to be delivered to the lungs as compared with only 10 percent for a jet nebulizer, along with improved chemical stability. Such an approach can be readily applied to many antibiotic compounds, including those for tuberculosis. The Purdue Office of Technology Commercialization has filed a patent on the innovation, and researchers are looking for partners to continue developing it.
www.purdue.edu/newsroom/releases/2018/Q4/new-2-in-1-powder-aerosol-to-upgrade-fight-against-deadly-superbugs-in-lungs.html That's interesting I wonder whether the relative large percentage of 60% is due to the structure of the combined antibiotics or to the inhaler. |
|
|
|
Post by bioexec25 on Jan 27, 2019 12:00:02 GMT -5
The percentage may have something to do with the number of potential small molecule candidates.
|
|
|
|
Post by mango on Jan 27, 2019 13:26:12 GMT -5
New 2-in-1 powder aerosol to upgrade fight against deadly superbugs in lungs—December 12, 2018 Now, Purdue researchers have invented a drug formulation that uses two synergistic antibiotics – colistin and ciprofloxacin – in one single particle that is shown to reach the infection sites in the deep lung area with the capability to kill multi-drug-resistant superbugs.“We are providing a promising option to fight the global crisis of antimicrobial resistance,” said Qi (Tony) Zhou, an assistant professor in Purdue’s College of Pharmacy, who leads the research team. “It has been a worldwide challenge to incorporate two antibiotics with different chemical properties into a single particle. Our novel formulation allows for a much more effective killing of drug-resistant bacteria in the deep lungs as two synergistic antibiotics can be simultaneously delivered to the same infection site.” Zhou said the technology is designed to save tens of thousands of lives from a variety of deadly lung infections, including people with cystic fibrosis and ventilator-assisted pneumonia. The Purdue innovation is a dry powder inhaler formulation, which is proving to be more effective and easier to use than conventional inhalation products delivered through nebulizers in most hospitals. Zhou said the Purdue formulation allows for more than 60 percent of drugs to be delivered to the lungs as compared with only 10 percent for a jet nebulizer, along with improved chemical stability. Such an approach can be readily applied to many antibiotic compounds, including those for tuberculosis. The Purdue Office of Technology Commercialization has filed a patent on the innovation, and researchers are looking for partners to continue developing it.
www.purdue.edu/newsroom/releases/2018/Q4/new-2-in-1-powder-aerosol-to-upgrade-fight-against-deadly-superbugs-in-lungs.html That's interesting I wonder whether the relative large percentage of 60% is due to the structure of the combined antibiotics or to the inhaler. I think it means like what brother said. >60% of drugs. Dont think they have developed & patented their own inhaler either |
|
|
|
Post by travis1953 on Jan 27, 2019 14:38:23 GMT -5
The percentage may have something to do with the number of potential small molecule candidates. Maybe I'm reading it different, "Zhou said the Purdue formulation allows for more than 60 percent of drugs to be delivered to the lungs as compared with only 10 percent for a jet nebulizer, along with improved chemical stability. Such an approach can be readily applied to many antibiotic compounds, including those for tuberculosis." I thought it meant 60% of the drug administered with each treatment. |
|
|
|
Post by mango on Jan 27, 2019 14:57:13 GMT -5
The percentage may have something to do with the number of potential small molecule candidates. Maybe I'm reading it different, "Zhou said the Purdue formulation allows for more than 60 percent of drugs to be delivered to the lungs as compared with only 10 percent for a jet nebulizer, along with improved chemical stability. Such an approach can be readily applied to many antibiotic compounds, including those for tuberculosis." I thought it meant 60% of the drug administered with each treatment. Oh yeah now I gotcha...hmm maybe you're right |
|
|
|
Post by lennymnkd on Jan 29, 2019 17:25:25 GMT -5
CNBC update/ Amgen CC ... pipeline migraines 🤔
|
|
|
|
Post by peppy on Jan 29, 2019 17:28:33 GMT -5
|
|
|
|
Post by mango on Feb 23, 2019 0:49:25 GMT -5
Commemoration Day Feb. 25 What better way to commemorate the passing of Al Mann on Monday than by Mike delivering a significant pipeline update, with four new projects, each one signifying each year since Al Mqnn's passing. Our partnership with Martine Rothblatt makes this year even more meaningful. 2016 - A triptan for migraine 2017 - 5HT3 Inhibitor for CINV 2018 - Tobramycin for CF 2019 - Undisclosed  |
|
|
|
Post by pantaloons on Feb 25, 2019 17:32:14 GMT -5
I was curious whether there was much discussion regarding antivertigo/antiemetic agents, such as meclizine, metoclopramide, or prochlorperazine. Acute management of vertigo and/or emesis may be a targetable symptom for the TI platform. I did not see these drug candidates on MNKD's pipeline presentation.
|
|
|
|
Post by cedafuntennis on Feb 25, 2019 18:02:17 GMT -5
Not maybe. He's definitely right. They can only measure the compound they are testing, cannot possibly expand the scope of a small trial to all products out there and deduct 60% of all of them...
|
|
|
|
Post by mango on Feb 26, 2019 10:12:15 GMT -5
Mike's Delivery fresh outta the oven!
|
|
|
|
Post by goyocafe on Feb 26, 2019 10:33:05 GMT -5
Mike's Delivery fresh outta the oven!
So, when does Trep-T Phase III start? I didn't hear any details on this call. Nice flyover, though. Or is UTHR going to tell us tomorrow? |
|
|
|
Post by mango on Feb 26, 2019 15:40:56 GMT -5
Mike's Delivery fresh outta the oven!
So, when does Trep-T Phase III start? I didn't hear any details on this call. Nice flyover, though. Or is UTHR going to tell us tomorrow? Mike mentioned it in the call. This year sometime, think he said earlier part of this year or something like that maybe. |
|
|
|
Post by mango on Feb 26, 2019 15:57:16 GMT -5
peppycannabidiol technosphere - various indications What do u think? peppy Cannabidiol Technosphere - various indications Single molecule CBD vs whole plant CBD-rich extract Single molecule CBD produces a bell-shaped, dose-response curve whereas whole plant CBD-rich extract does not. The entourage effect. Curious to see how RLS & MannKind's CBD Technosphere formulation performs and what indications they are targeting.
|
|
